03/04/15 - 01:47 PM EST
The new Opdivo approval covers patients with squamous non-small cell lung cancer no longer responsive to chemotherapy, according to an announcement made the FDA.READ FULL POST
03/02/15 - 08:15 AM EST
Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.READ FULL POST
02/25/15 - 07:55 AM EST
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.READ FULL POST
02/20/15 - 03:47 PM EST
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.READ FULL POST
02/11/15 - 09:04 AM EST
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.READ FULL POST
02/09/15 - 08:36 AM EST
Keryx Biopharmaceuticals gave all 12 of the investment banks with research coverage of the company a slice of its $110 million stock offering.READ FULL POST
02/03/15 - 07:59 AM EST
An experimental diabetes drug from Isis looks good when the effect is measured at 36 weeks, but the study was designed to measure the end point at 27 weeks.READ FULL POST
02/02/15 - 12:22 PM EST
Gilead Sciences reports fourth-quarter and 2014 earnings on Tuesday after the market close.READ FULL POST
01/30/15 - 06:01 AM EST
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.READ FULL POST
01/29/15 - 07:44 AM EST
If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.READ FULL POST
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.